Exelixis expects revenue for the fourth quarter to be $415M. Consensus at $414.83M. For 2022, the company sees revenue of $1.6B. Consensus at $1.6B. The company also said it expects 2023 revenue of $1.775B-$1.875B. Consensus at $1.83B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- NccRCC ‘material expansion opportunity’ for Exelixis, says William Blair
- Exelixis announces initiation of STELLAR-304 Phase 3 trial of zanzalintinib
- Exelixis names Dana Aftab next chief scientific officer
- Exelixis price target lowered to $32 from $35 at Truist
- Exelixis’ Therapy Fails in Phase 3 NSCLC Trial